natgillin/translations-raw huggingface dataset:
Moreover the antibody response to measles vaccine decreases as the level of immunosuppression increases.
Tudi odziv protiteles na cepivo proti ošpicam se manjša z naraščanjem ravni imunosupresije.
For this reason and to reflect the most recent information, the immunogenicity data were differentiated between two groups: “Immune response in children 12 months and older” and “Immune response in children aged 9 to 10 months”.
Zaradi tega razloga in za prikaz najnovejših informacij so bili podatki o imunogenosti razdeljeni na dve skupini: „Imunski odziv pri otrocih, starih 12 mesecev in več“ in „Imunski odziv pri otrocih, starih 9 do 10 mesecev“.
Priorix is nationally approved in 20 countries and is approved through the mutual recognition procedure (MRP) in 9 countries.
Cepivo Priorix je v 20 državah odobreno po nacionalnem postopku, v 9 državah pa je odobreno v okviru postopka z medsebojnim priznavanjem.
The theoretical teratogenic risk following rubella vaccination has been estimated to be 0.5% during the first trimester and is up to 1.6%, if the vaccine is given between 1-2 weeks before and 4-6 weeks after conception.
Teoretično teratogeno tveganje po cepljenju proti rdečkam je bilo ocenjeno na 0,5 % v prvem trimesečju in znaša največ 1,6 %, če se cepivo injicira 1-2 tedna pred spočetjem in 4-6 po njem.
The available data do not suggest that co-administration of these vaccines has an impact on the immunogenicity and safety of the antigens tested.
Razpoložljivi podatki ne kažejo, da ima sočasna uporaba teh cepiv vpliv na imunogenost in varnost preskušenih antigenov.
This was endorsed by the CHMP following review and assessment of the clinical study report that was submitted to support the coadministration of Priorix with this vaccine.
CHMP je to odobril, ko je pregledal in ocenil poročilo klinične študije, predloženo v podporo sočasnemu dajanju cepiva Priorix s temi cepivi.
Because of the much higher likelihood of thrombocytopenia after natural infection, the benefits of vaccination most often exceed the risks of severe symptomatic thrombocytopenia caused by immunization.
Zaradi veliko večje verjetnosti trombocitopenije po naravni okužbi so koristi cepljenja največkrat večje od tveganj hude simptomatske trombocitopenije, ki jih povzroči imunizacija.
The final agreed wording is: “Women who intend to become pregnant should be advised to delay for 1 month following PRIORIX vaccination.
Dogovorjeno je bilo naslednje končno besedilo: „Ženskam, ki nameravajo zanositi, je treba svetovati, naj zanositev prestavijo na obdobje 1 mesec po cepljenju s cepivom PRIORIX.
The MAH was asked to add some information on this issue.
Imetnik dovoljenja za promet z zdravilom je bil naprošen, da v zvezi s tem doda nekaj informacij.
Natural rubella infection can have a devastating impact on pregnancy, leading to foetal death, premature delivery and an array of congenital defects.
Naravna okužba z virusom rdečk ima lahko na nosečnost poguben vpliv in povzroči smrt plodu, prezgodnji porod in vrsto prirojenih okvar.
There is currently no information to conclude that there is a teratogenic risk following vaccination with MMR vaccines however the theoretical concern remains.
Trenutno ni informacij, po katerih bi lahko sklepali na obstoj teratogenega tveganja po cepljenju, vendar teoretični pomislek ostaja.
The MAH accepted the new text and also added a sentence on the monitoring of those patients which was endorsed by the CHMP.
Imetnik dovoljenja za promet je novo besedilo sprejel in dodal stavek o spremljanju teh bolnikov, ki ga je CHMP vključil.
The CHMP noted that the current clinical experience with Priorix is limited to children and no trials were performed in adolescents and adults.
CHMP je opazil, da so trenutne klinične izkušnje s cepivom Priorix omejene na otroke in da preskušanj pri mladostnikih in odraslih niso opravili.
As there is still a theoretical teratogenic risk connected to rubella containing vaccines it was agreed that this very vulnerable group should not be put at risk.
Ker je s cepivi, ki vsebujejo virus rdečk, še vedno povezano teoretično teratogeno tveganje, je bilo dogovorjeno, da se te zelo ranljive skupine ne izpostavi tveganjem.
More specifically: “For use in children between 9 to 12 months of age see sections 4.2, 4.4 and 5.1.” The MAH had also included in this section the sentence “The use of PRIORIX should be based on official recommendations.” but the CHMP agreed to move it at the beginning of section 4.2 Posology and method of administration because as per the guideline on SmPC dated September 2009 the reference to official recommendations should be made under section 4.2.
Natančneje: „Za uporabo pri otrocih, starih od 9 do 12 mesecev, glejte poglavja 4.2, 4.4 in 5.1.“ Imetnik dovoljenja za promet z zdravilom je v to poglavje vključil tudi stavek „Uporaba cepiva PRIORIX mora temeljiti na uradnih priporočilih.“, vendar je bil v soglasju z odborom CHMP ta stavek premeščen na začetek poglavja 4.2 Odmerjanje in način uporabe, saj je treba v skladu s smernicami za povzetek glavnih značilnosti zdravila, izdanimi septembra 2009, sklicevanje na uradna priporočila vključiti v poglavje 4.2.
Although women should be asked about the possibility of early pregnancy prior to vaccination, screening tests to exclude pregnancy are not required.
Čeprav je treba ženske pred cepljenjem vprašati, ali so morda v zgodnji fazi nosečnosti, presejalnih testov za izključitev nosečnosti ni treba izvajati.
The vaccine is a lyophilised vaccine preparation, which is reconstituted with separately supplied sterile diluent (water for injection) prior to use.
Cepivo je liofilizirano in se pred uporabo rekonstituira s posebej dobavljenim sterilnim vehiklom (vodo za injekcije).
Approximately 85% of pregnancies will be negatively affected when rubella infection occurs during the first trimester.
Okužba z virusom rdečk negativno vpliva na približno 85 % nosečnosti, če se pojavi v prvem trimesečju.
Priorix is contraindicated in pregnant women.
Cepivo Priorix je kontraindicirano pri nosečnicah.
Compared with 2009, the number of cases in 2010 more than tripled in infants below one year of age, and increased fivefold in adults 20-29 years old.
V primerjavi z letom 2009 se je število primerov v letu 2010 pri otrocih, starih manj kot eno leto, več kot potrojilo, pri odraslih, starih od 20 do 29 let, pa se je povečalo za petkrat.
The MAH amended this paragraph as per the CHMP's recommendation and also added in the list one more vaccine (10-valent pneumococcal conjugate vaccine).
Imetnik dovoljenja za promet z zdravilom je ta odstavek spremenil po priporočilih CHMP in na seznam dodal še eno cepivo (10-valentno konjugirano cepivo proti pnevmokokom).
In conclusion, based on the clinical data the lower age limit of the indication is endorsed, however since the immune response following a single dose of Priorix is lower in children under 12 months of age a reference to sections 4.2, 4.4 and 5.1 has been included.
Klinični podatki torej kažejo, da je treba podpreti nižjo starostno mejo za omenjeno indikacijo, vendar pa je zaradi manjšega imunskega odziva po enem odmerku cepiva Priorix pri otrocih, starih manj kot 12 mesecev, treba vključiti sklic na poglavja 4.2, 4.4 in 5.1.
In addition experiences with other MMR or MMRV (measles, mumps, rubella, varicella) vaccines do not indicate any negative impact on the immune response or safety profile following intramuscular injection.
Tudi izkušnje z drugimi cepivi MMR ali MMRV (ošpice, mumps, rdečke, norice) ne kažejo na negativen vpliv na imunski odziv ali varnostni profil po intramuskularnem injiciranju.
The immunogenicity data however clearly demonstrate that lower antibody responses against measles and mumps are observed in children aged 9 to 11 months at the time of primary immunization than in older children which is most likely due to circulating maternal antibodies or the immaturity of the immune system.
Vendar pa podatki o imunogenosti nedvoumno dokazujejo manjši odziv protiteles proti ošpicam in mumpsu pri otrocih, starih od 9 do 11 mesecev, v času primarne imunizacije kot pri starejših otrocih, kar je najverjetneje posledica materinih protiteles v obtoku ali nezrelosti imunskega sistema.
The CHMP therefore suggested adding the information from a recent systematic review that “MMR-associated thrombocytopenia is rare and generally self-limited”.
Zato je CHMP predlagal, da se doda informacija iz novejše sistematske revizije, da je „trombocitopenija, povezana s cepivi MMR, redka in običajno samoomejujoča“.
A number of studies documented increased risk of developing mumps with increasing time after vaccination (Vandermeulen et al., 2004; Cortese et al., 2008; Castilla et al., 2009), and data from the United Kingdom indicate vaccine effectiveness may decrease with age, which probably also reflects increasing time from vaccination (Cohen et al., 2007).
Številne študije so dokumentirale, da se tveganje za razvoj mumpsa veča s potekom časa po cepljenju (Vandermeulen et al., 2004; Cortese et al., 2008; Castilla et al., 2009), podatki iz Združenega kraljestva pa kažejo, da se lahko učinkovitost cepiva s starostjo slabša, kar verjetno kaže tudi na pretek časa od cepljenja (Cohen et al., 2007).
Finally, the CHMP asked the seroconversion rates given to be replaced by more recent data reported for the Human Serum Albumin-free (HSA-free) formulation of Priorix and also asked the MAH if there are any immunogenicity data available from the Human Serum Albumin-free (HSAfree) formulation in children below 12 months of age.
Končno je odbor CHMP zaprosil, da se navedene stopnje serokonverzije nadomestijo z novejšimi podatki, ki so bili poročani za formulacijo cepiva Priorix brez albumina iz človeškega seruma (brez HSA), in imetnika dovoljenja za promet z zdravilom vprašal, ali so na voljo podatki o imunogenosti za formulacijo brez albumina iz človeškega seruma (brez HSA) pri otrocih, starih manj kot 12 mesecev.
The CHMP noted that recent data from an outbreak in France indicate that the highest incidence of measles infections was observed in infants below 1 year of age, followed by children between one and two years old.
Odbor CHMP je ugotovil, da novejši podatki o izbruhu bolezni v Franciji kažejo na večjo pojavnost okužb z ošpicami pri dojenčkih, starih manj kot 1 leto, sledijo pa otroci, stari med enim in dvema letoma.
The MAH was asked to consider adding an overview of vaccine immunogenicity assessment (clinical trials), and to add vaccine efficacy figures as well, if available, or to mention their inexistence.
Imetnik dovoljenja za promet z zdravilom je bil naprošen, da razmisli o vključitvi pregleda ocene imunogenosti cepiva (klinična preskušanja), in da doda tudi številke o učinkovitosti cepiva, če so na voljo, ali da omeni, da ne obstajajo.
Priorix is contraindicated in pregnancy but since there is currently no information to conclude that there is a teratogenic risk following vaccination with MMR vaccines the following wording was agreed: “PRIORIX is contraindicated during pregnancy (see section 4.3).
Cepivo Priorix je kontraindicirano pri nosečnicah, vendar je bilo zaradi neobstoja informacij, iz katerih bi lahko sklepali na teratogeno tveganje po cepljenju s cepivi MMR, dogovorjeno naslednje besedilo: „Cepivo PRIORIX je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
As regards the intramuscular route of administration no information was provided in the updated clinical dossier, but was provided in the initial application for marketing authorisation.
Glede intramuskularne poti dajanja v posodobljeni klinični dokumentaciji ni bilo podatkov, so pa bili ti vključeni v začetni vlogi za dovoljenje za promet z zdravilom.
The main divergences between the proposed harmonized SmPC and national product information relates to the description of post marketing reports.
Glavna razlika med predlaganim usklajenim povzetkom glavnih značilnosti zdravila in nacionalnimi informacijami o zdravilu se nanaša na opis poročil iz obdobja trženja.
Inadvertent vaccination of unknowingly pregnant women with PRIORIX should not be a reason for termination of pregnancy”.
Nenamerno cepljenje žensk, ki so noseče, pa tega ne vedo, s cepivom PRIORIX, ni vzrok za prekinitev nosečnosti“.
The geometric mean titers (GMTs) for seroconverters were 2431.9 mIU/ml, 1010.0 U/ml and 67.1 IU/ml for the anti-measles, anti-mumps and anti-rubella antibodies, respectively which were slightly lower than the values reported following subcutaneous administration (2958 mIU/ml, 1400 U/ml and 73 IU/ml, respectively).
Geometrična povprečja titrov (GMT) za serokonverterje so bila 2 431,9 mil. i.e./ml za protitelesa proti ošpicam, 1 010,0 e./ml za protitelesa proti mumpsu in 67,1 i.e./ml za protitelesa proti rdečkam, kar je nekoliko nižje kot vrednosti, o katerih so poročali po subkutanem dajanju (2 958 mil. i.e./ml, 1 400 e./ml in 73 i.e./ml).
Section 4.4 - Special warnings and precautions for use To be in line with the SmPC guideline the company proposed to:
Poglavje 4.4 - Posebna opozorila in previdnostni ukrepi Za zagotovitev skladnosti s smernicami za povzetek glavnih značilnosti zdravila družba predlaga:
The sentence was modified as per the QRD recommendation to read “PRIORIX has not been evaluated in fertility studies”.
Stavek je bil spremenjen po priporočilu za pregledovanje kakovosti dokumentov (QRD) in se sedaj glasi „Cepiva PRIORIX v študijah plodnosti niso proučili.“
The data available do not suggest any clinically relevant interference in the antibody response to each of the individual antigens (Carmona et al., 2010; Pace et al., 2008).
Razpoložljivi podatki ne kažejo klinično pomembnega medsebojnega delovanja pri nastajanju protiteles proti vsakemu posameznemu antigenu (Carmona et al., 2010; Pace et al., 2008).
The wording of this paragraph was amended as follows: “In subjects who have received human gammaglobulins or a blood transfusion, vaccination should be delayed for three months or longer (up to 11 months) depending on the dose of human globulins administered because of the likelihood of vaccine failure due to passively acquired measles, mumps and rubella antibodies”.
Besedilo tega odstavka je bilo spremenjeno, kot sledi: „Pri posameznikih, ki so prejeli transfuzijo humanih gamaglobulinov ali krvi, je treba cepljenje prestaviti za tri mesece ali več (do 11 mesecev), odvisno od odmerka uporabljenih humanih globulinov, zaradi verjetnosti, da cepivo ne bo delovalo kot posledica pasivno pridobljenih protiteles proti ošpicam, mumpsu in rdečkam.“
If not given at the same time, an interval of at least one month is recommended between administration of PRIORIX and other live attenuated vaccines.
Če se cepiva ne dajo sočasno, se med cepljenjem s cepivom PRIORIX in drugimi živimi oslabljenimi cepivi priporoča vsaj enomesečni presledek.
Only in the event the child is confirmed or suspected to be immunodeficient, risks and benefits of vaccinating the mother should be evaluated (see section 4.3)”.
Samo če je imunska pomanjkljivost pri otroku potrjena ali pri sumu nanjo je treba oceniti razmerje med tveganji in koristmi pri cepljenju matere (glejte poglavje 4.3)“.
Vaccinees with a history of febrile convulsions should be closely followed-up.”
Cepljene osebe z anamnezo vročinskih krčev je treba skrbno spremljati.“
Transmission of the rubella vaccine virus to infants via breast milk as well as transplacental transmission has been documented without any evidence of clinical disease.”
Prenos virusa iz cepiva proti rdečkam na dojenčke z materinim mlekom in prenos prek placente je bil dokumentiran, vendar ni dokazov o klinični bolezni.“
The Advisory Committee on Immunization Practices (ACIP) shortened its recommended period in 2001 to avoid pregnancy after receipt of rubella-containing vaccine from 3 months to 28 days because no case of CRS had been identified among infants born to women who were vaccinated inadvertently against rubella within 3 months or early in pregnancy (Center for Disease Control and Prevention, 2001).
Svetovalni odbor za imunizacijo (ACIP - Advisory Committee on Immunization Practices) je priporočeno obdobje leta 2001 skrajšal, da prepreči nosečnost po cepljenju s cepivom, ki vsebuje rdečke, s 3 mesecev na 28 dni, saj med dojenčki, rojenimi ženskam, ki so jih v 3 mesecih ali zgodaj med nosečnostjo nehote cepili proti rdečkam, niso odkrili nobenega primera kongenitalnega sindroma rdečk (Center za nadzor in preprečevanje bolezni, 2001).
adapt the wording about HIV+ subjects and hypersensitivity to vaccine components to align with section 4.3.
prilagoditev besedila o posameznikih, okuženih z virusom HIV, in o preobčutljivosti na sestavine cepiva zaradi skladnosti s poglavjem 4.3,
The CHMP also noted that the contraindication for immune-depressed humans might need a general rewording in all MMR vaccines following the progress of science and the important knowledge of the immunology.
CHMP je pripomnil tudi, da bi bilo morda treba kontraindikacije za osebe s pomanjkljivim imunskim odzivom v celoti prenoviti za vsa cepiva MMR zaradi napredka znanosti in pomembnih imunoloških dognanj.
Based on the assessment of all data, the Marketing Authorisation Holder (MAH) proposed to align the indication of Priorix to children aged from 9 months old using the following wording: “PRIORIX is indicated for the active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.”
Na podlagi ocene vseh podatkov je imetnik dovoljenja za promet z zdravilom predlagal uskladitev indikacije za cepivo Priorix za otroke, stare 9 mesecev in več, z uporabo naslednjega besedila: „Cepivo PRIORIX je indicirano za aktivno imunizacijo otrok, starih 9 mesecev ali več, mladostnikov in odraslih proti ošpicam, mumpsu in rdečkam.“
Moreover, in the reference note for encephalitis the MAH was asked to add the risk of encephalitis after mumps infection, “mumps: 2-4 in 1000 cases”.
Imetnik dovoljenja za promet z zdravilom je bil naprošen tudi, da v opombo s sklicem na encefalitis doda tveganje encefalitisa po okužbi z mumpsom; „mumps: 2-4 od 1 000 primerov“.
In general, the MAH proposed a harmonised text drafted mainly using as basis the one approved in the MRP procedure with some amendments.
Imetnik dovoljenja za promet z zdravilom na splošno predlaga usklajeno besedilo, ki temelji na besedilu, odobrenem v postopku z medsebojnim priznavanjem, z nekaterimi spremembami.
The MAH was asked to consider adding a specific overview of immunogenicity assessment in infants vaccinated at an age below 12 months, with month-specific figures if available, for a first dose, as well as an overview of the assessment of an early second dose.
Imetnik dovoljenja za promet z zdravilom je bil naprošen, da razmisli o vključitvi specifičnega pregleda ocene imunogenosti pri otrocih, cepljenih pri starosti pod 12 mesecev, s številkami po mesecih, če so na voljo, za prvi odmerek, in s pregledom ocene zgodnjega drugega odmerka.
In summary, the CHMP supported the proposal of the MAH which was “Humoral or cellular immune deficiency (primary or acquired), including hypogammaglobulinaemia, dysgammaglobulinaemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage <25%”.
Če povzamemo, CHMP podpira predlog imetnika dovoljenja za promet z zdravilom, ki je bil „Humoralna ali celična (primarna ali pridobljena) imunska pomanjkljivost, vključno s hipogamaglobulinemijo, disgamaglobulinemijo in aidsom, simptomatska okužba z virusom HIV ali starostno specifični odstotek CD4+ T-limfocitov < 25 %“.
MMR-associated thrombocytopenia is rare and generally self-limited.
Trombocitopenija, povezana z MMR, je redka in običajno samoomejujoča.
The CHMP noted that for the majority of clinical trials investigating co-administration of Priorix with other vaccines no CSRs are available but only literature references.
CHMP je ugotovil, da za večino kliničnih preskušanj, v katerih preučujejo sočasno uporabo cepiva Priorix z drugimi cepivi, ni na voljo poročil klinične študije, temveč samo navedbe literature.
The theoretical maximum risk for CRS after administration of the vaccine at 1.6%, is much lower than the risk of major non-CRS induced congenital defects during pregnancy (Bozzo et al., 2011).
Teoretično največje tveganje za KSR po uporabi cepiva znaša 1,6 %, kar je veliko manjše kot tveganje velikih prirojenih okvar, ki jih med nosečnostjo povzročijo drugi vzroki, ki ne vključujejo KSR (Bozzo et al., 2011).
This was endorsed by the CHMP.
CHMP je stavek odobril.
In addition as there was one inconsistency with the package leaflet the MAH was asked to add “atypical mild or attenuated measles” in section 4.8 under infections and infestations.
Poleg tega je bila v navodilu za uporabo ena nedoslednost, zato je bil imetnik dovoljenja za promet z zdravilom naprošen, da doda „neobičajno blage ali oslabljene ošpice“ v poglavju 4.8 pod infekcijske in parazitske bolezni.
Though available data in the literature highlight a valuable perspective with regard to the overall risk of vaccine exposure at various stages of pregnancy, the theoretical risk, and because it is impossible to prove that the risk is zero, the MAH proposed that known pregnancy remains a contraindication to administration of rubella-containing vaccine.
Čeprav razpoložljivi podatki iz literature osvetljujejo dragocen vidik glede splošnega tveganja izpostavljenosti cepivu v različnih obdobjih nosečnosti, je zaradi teoretičnega tveganja in ker je nemogoče dokazati, da je tveganje ničto, imetnik dovoljenja za promet z zdravilom predlagal, da ostane znana nosečnost še naprej kontraindikacija za uporabo cepiva, ki vsebuje virus rdečk.
In order to get more insight in possible harm of MMR vaccination during pregnancy or pre-conception the CHMP asked from the MAH to provide evidence from enhanced surveillance and controlled studies that focus on risk of spontaneous abortion in women susceptible to measles, mumps and/or rubella, risk of malformation and congenital rubella syndrome (CRS) in offspring of such women, follow-up data up to 1 year age of children born from rubella susceptible women.
Zaradi boljšega vpogleda v možno škodo, ki jo lahko cepivo MMR povzroči med nosečnostjo ali pred spočetjem, je CHMP imetnika dovoljenja za promet z zdravilom zaprosil za dokaze o povečanem spremljanju in kontroliranih študijah, ki se osredotočajo na tveganje spontanega splava pri ženskah, dovzetnih za ošpice, mumps in/ali rdečke, tveganje malformacij in kongenitalnega sindroma rdečk (KSR) pri potomcih teh žensk, in podatke o spremljanju do 1 leto po rojstvu za otroke žensk, dovzetnih za rdečke.
The CHMP agreed that the list of adverse reactions reported from clinical trials and post marketing experience was appropriately reflected in the proposed harmonized SmPC.
CHMP se je strinjal, da je seznam neželenih učinkov, o katerih so poročali iz kliničnih preskušanj in iz izkušenj v obdobju trženja zdravila, ustrezno naveden v predlaganem usklajenem povzetku glavnih značilnosti zdravila.
The MAH replaced the seroconversion rates and stated data from children below 12 months of age are yet to come as a study is currently being conducted.
Imetnik dovoljenja za promet z zdravilom je stopnje serokonverzije zamenjal in navedel, da bodo podatki za otroke, stare manj kot 12 mesecev, kmalu na voljo, saj študija trenutno poteka.
Vaccination of breastfeeding women with measles, mumps or rubella vaccines has not been related with any safety problem for the women or their infants, although there is limited experience with Priorix during breastfeeding.
Cepljenje nosečnic s cepivi proti ošpicam, mumpsu ali rdečkam ni povezano s kakršnim koli tveganjem za varnost za ženske ali njihove dojenčke, čeprav so izkušnje s cepivom Priorix med dojenjem omejene.
The intramuscular route of administration was initially investigated in a small number of subjects (N=40) with seroconversion rates of 96.7%, 97.5% and 100% against measles, mumps and rubella, respectively.
Intramuskularna pot dajanja je bila uvodoma raziskana pri majhnem številu oseb (n = 40) s stopnjo serokonverzije 96,7 % proti ošpicam, 97,5 % proti mumpsu in 100 % proti rdečkam.